Empowered Funds LLC Purchases 7,367 Shares of DexCom, Inc. $DXCM

Empowered Funds LLC raised its position in DexCom, Inc. (NASDAQ:DXCM) by 71.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,623 shares of the medical device company’s stock after acquiring an additional 7,367 shares during the quarter. Empowered Funds LLC’s holdings in DexCom were worth $1,107,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. V Square Quantitative Management LLC increased its stake in shares of DexCom by 1.8% during the 1st quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock worth $604,000 after purchasing an additional 172 shares during the last quarter. Essex Financial Services Inc. raised its holdings in shares of DexCom by 5.7% in the 1st quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock valued at $204,000 after purchasing an additional 175 shares during the period. Keel Point LLC lifted its stake in DexCom by 3.1% in the 4th quarter. Keel Point LLC now owns 6,473 shares of the medical device company’s stock valued at $430,000 after purchasing an additional 193 shares during the last quarter. Integrated Wealth Concepts LLC lifted its stake in DexCom by 6.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after purchasing an additional 196 shares during the last quarter. Finally, Gabelli Funds LLC lifted its stake in DexCom by 0.4% in the 4th quarter. Gabelli Funds LLC now owns 50,200 shares of the medical device company’s stock valued at $3,332,000 after purchasing an additional 200 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DXCM stock opened at $84.75 on Friday. The company has a market capitalization of $31.98 billion, a price-to-earnings ratio of 33.50, a PEG ratio of 1.42 and a beta of 1.41. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. The company has a 50-day simple moving average of $74.42 and a 200 day simple moving average of $69.73. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $87.85.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. The business had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. DexCom’s quarterly revenue was up 13.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.48 EPS. On average, sell-side analysts predict that DexCom, Inc. will post 2.65 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. JPMorgan Chase & Co. boosted their price target on DexCom from $65.00 to $82.00 and gave the stock a “neutral” rating in a research report on Friday, July 31st. Deutsche Bank Aktiengesellschaft started coverage on DexCom in a research note on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 price objective on the stock. TD Cowen reaffirmed a “buy” rating on shares of DexCom in a research report on Friday, July 31st. Canaccord Genuity Group set a $90.00 target price on DexCom and gave the stock a “buy” rating in a research note on Monday, August 3rd. Finally, Barclays reissued an “underweight” rating and set a $64.00 target price (down from $67.00) on shares of DexCom in a report on Monday, May 18th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $88.71.

Insider Transactions at DexCom

In other news, Director Mark G. Foletta sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $85.32, for a total transaction of $170,640.00. Following the completion of the sale, the director owned 48,852 shares in the company, valued at $4,168,052.64. The trade was a 3.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,911 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $74.13, for a total value of $364,052.43. Following the completion of the transaction, the executive vice president directly owned 95,450 shares in the company, valued at $7,075,708.50. The trade was a 4.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 102,506 shares of company stock worth $7,535,898. Insiders own 0.28% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.